BridgeBio Shares Fall As Initial-Stage Rare Metabolic Disorder Study Kicks-off


BridgeBio Pharma BBIO has dosed first patient in its Phase 1 clinical trial of BBP-671, an investigational oral therapy being developed for the potential treatment of conditions caused by coenzyme A (CoA) deficiencies. 

The Phase 1 study is a single- and multiple-ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BBP-671.

In this second part of the trial, up to eight propionic acidemia (PA) patients and eight methylmalonic acidemia (MMA) patients will receive BBP-671.

PA and MMA are rare metabolic disorders caused by mutations in genes that impact the development of enzymes that participate in amino acid metabolism, leading to life-threatening metabolic decompensations.

Uma Sinha, Chief Scientific Officer, commented: "We are excited by biomarker changes observed with BBP-671 in a preclinical study using a mouse model for PA, which were associated with improved survival.  Individuals diagnosed with PA and MMA and their families currently have no treatment options beyond dietary management and liver and/or kidney transplant, and we hope that BBP-671 may represent a novel therapeutic strategy for these diseases."

Initial data readout from the second part of this clinical trial are expected in the first half of 2023.

Price Action : BridgeBio shares are trading around 5 percent down at $10.10 on Thursday at the time of publication.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechHealth CareSmall CapGeneralPatient Enrollment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!